مباشر

Endpoints NewsDimension seeks up to $750M for third life sciences fund after string of success Endpoints NewsElevance talks 'practical' AI Endpoints NewsMammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once again FierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug CellPaleogenomes reveal the evolutionary relationship between modern and cave lions Endpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cuts Endpoints NewsSupreme Court sides with Hikma in 'skinny label' case FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic BioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2B FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

Endpoints News ٤ يونيو ٢٠٢٦

Novo Holdings backs European fund; Alnylam sends second obesity drug into clinic

Plus news about IMU Biosciences, Autobahn and Jade Biosciences. 💸 Novo Holdings invests in Europe-focused fund: The investment manager of the Novo Nordisk Foun...

Plus news about IMU Biosciences, Autobahn and Jade Biosciences. 💸 Novo Holdings invests in Europe-focused fund: The investment manager of the Novo Nordisk Foundation's fortunes is backing the Scaleup Europe Fund with €500 million.